Literature DB >> 10794706

Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements.

R M Schelkun1, P W Yuen, K Serpa, L T Meltzer, L D Wise, E R Whittemore, R M Woodward.   

Abstract

Previous work in our laboratories investigating compounds with structural similarity to ifenprodil (5) and 6 (CP101,606) resulted in compound 7 as a potent and selective antagonist of the NR1/2B subtype of the NMDA receptors. Replacement of the phenol group of 7 with a benzimidazalone group tethered by a three-carbon chain to 4-benzylpiperidine resulted in a slightly less active, but selective, compound. Lengthening the carbon tether resulted in a decrease in NR1/2B potency. Replacement of the phenol ring with a hydantoin resulted in weak antagonists. Compound 11a was one of the most potent NR1/2B antagonists from this study. Compound 11a also potentiated the effects of L-DOPA in a rat model of Parkinson's disease (the 6-hydroxydopamine-lesioned rat), dosed at 30 mg/kg orally.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794706     DOI: 10.1021/jm990537r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  An MCASE approach to the search of a cure for Parkinson's Disease.

Authors:  Gilles Klopman; Aleksandr Sedykh
Journal:  BMC Pharmacol       Date:  2002-04-02

Review 2.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.